Serum interferon in Navajo children with severe combined immunodeficiency disease inhibits lymphoblastogenesis.

Important note: Information in this article was accurate in 1983. The state of the art may have changed since the publication date.

Serum interferon in Navajo children with severe combined immunodeficiency disease inhibits lymphoblastogenesis.

J Clin Immunol. 1983 Jan;3(1):14-21. Unique Identifier : AIDSLINE MED/83136163
Jones JF; Minnich LM; Lucas DO; Fulginiti VA; Ingham Z; Langford MP; Stanton GJ

Abstract: Two Navajo Indian children with severe combined immunodeficiency disease (SCID) lost reconstituted immune function after virus infections. A serum factor which inhibited normal lymphocyte response to mitogens was found in one of them and led to the examination of sera from five other Navajos with SCID. Mean inhibition by six Navajo sera was 67%; no inhibitor was found in sera from normal adults and children. The inhibitor activity was nondialyzable and heat stable, yet partially sensitive to pH 2.0, suggesting that interferon(s) was present. Interferon (IFN) activity in patient sera ranged from 10 to 300 U/ml. Normal children had peak serum IFN levels of 100 and 30 U/ml in the acute and convalescent periods, respectively, of virus infections. IFN alpha, IFN beta, and IFN gamma were identified in SCID sera by specific antisera. Both inhibitor and IFN activities in three Navajo sera were 88-95 and 89-100%, respectively, removed with anti-IFN antisera. Similar patterns of inhibition of lymphoblastogenesis were seen with IFN standards. IFN levels in the SCID patients did not correlate with documented infections; elevated levels were present when no infections could be documented. The immunologic imbalances in some forms of SCID may be related to circulating inhibitors, possibly interferon.

Keywords: Arizona Case Report Female Human Immunologic Deficiency Syndromes/BLOOD/COMPLICATIONS/*IMMUNOLOGY/ THERAPY *Indians, North American Infant Infant, Newborn Interferons/*BLOOD/IMMUNOLOGY *Lymphocyte Transformation Male Thymus Gland/TRANSPLANTATION Virus Diseases/COMPLICATIONS JOURNAL ARTICLE

830630
M8360026

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1983. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1983. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .